The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The discovery in 1911 that electrons emitted in beta decay have a continuous rather than a discrete spectrum appeared to contradict conservation of energy, under the then-current assumption that beta decay is the simple emission of an electron from a nucleus. This problem was eventually resolved in 1933 by Enrico Fermi who proposed the correct description of beta-decay as the emission of both an electron and an antineutrino, which carries away the apparently missing energy.
Plant development is the process by which structures originate and mature as a plant grows. It is a subject studied in plant anatomy and plant physiology as well as plant morphology. The process of development in plants is fundamentally different from that seen in vertebrate animals. When an animal embryo begins to develop, it will very early produce all of the body parts that it will ever have in its life. When the animal is born (or hatches from its egg), it has all its body parts and from that point will only grow larger and more mature. By contrast, plants constantly produce new tissues and structures throughout their life from meristems located at the tips of organs, or between mature tissues. Thus, a living plant always has embryonic tissues. The properties of organisation seen in a plant are emergent properties which are more than the sum of the individual parts. "The assembly of these tissues and functions into an integrated multicellular organism yields not only the characteristics of the separate parts and processes but also quite a new set of characteristics which would not have been predictable on the basis of examination of the separate parts." In other words, knowing everything about the molecules in a plant are not enough to predict characteristics of the cells; and knowing all the properties of the cells will not predict all the properties of a plant's structure.
== History == Labetalol was the first drug created that combined both α- and β-adrenergic receptor blocking properties. It was created to potentially fix the compensatory reflex issue that occurred when blocking a single receptor subtype, i.e. vasoconstriction after blocking β-adrenergic receptors or tachycardia after blocking α-adrenergic receptors. Because the reflex from blocking the single receptor subtypes acted to prevent the lowering of blood pressure, it was postulated that weak blocking of both α- and β-adrenergic receptors could work together to decrease blood pressure.
Sources: en.wikipedia.org
Director, Chuckling Goat. For services to Charity and to Innovation in Wales. Evelyn Mary Joy. Agent, Buckingham Conservative Association. For Political and Public Service. James Michael Keggen. Coxswain, Port St Mary Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Sharon Elaine Kelly. Project Manager, Royston Youth Action. For services to Young People. Lindsey Kemp. Officer, National Crime Agency. For services to Law Enforcement. Maurice Joseph Kennedy. Volunteer, Transport Training Board. For services to the Transport and Logistics Industries of Northern Ireland and Great Britain. Christine Anne Kenyon. Deputy Principal, The Manchester College, Greater Manchester. For services to Further Education. Michael Kettle. Explosives Officer, Metropolitan Police Service. For services to Bomb Disposal. Helen Morag Keys. Entrepreneur, Queen's University's Students' Union. For services to Entrepreneurship and Innovation in Farming. Jasdeep Hari Bhajan Singh Khalsa. Founder, The Sikher Project. For charitable services to the Sikh Community. Professor Saye Hock Khoo. Professor of Pharmacology and Therapeutics, University of Liverpool. For services to Infectious Diseases and Pharmacology. Virginia Kiddle. Officer, National Crime Agency. For services to Law Enforcement. Amy Kilby. UK Representative, International Project Management Organisation. For services to Military Communications. James Kilpatrick. Chair, RVH Liver Support Group. For services to People with Liver Disease and their Carers in Northern Ireland. Charline Zephoria King.
=== Precision Medicine === The protease modulatory web represents opportunities to identify novel biomarkers for disease and targets for drug design. Proteolytic processed N-termini have been proposed as potential biomarkers as disease specific proteolysis has been well studied in pathologies such as inflammation and cancer. Contributions to degradomics have identified numerous characterized and novel protease substrates and continue to lead to speculation of previously unknown protease targets. More recently, proteolytic signatures of cell death have been found using N-terminomic techniques on chemotherapy patient plasma samples. Advancements in SRM and MRM clinical assays also allow for analyzing proteolytic signature biomarkers in patient samples and can be complemented by PSP quantification. Deciphering these networks will aid drug design in understanding which substrates perform useful roles versus harmful ones to determine which should be targeted by drugs.
Known instances of nuclear reactions, aside from producing energy, also produce nucleons and particles on readily observable ballistic trajectories. In support of their claim that nuclear reactions took place in their electrolytic cells, Fleischmann and Pons reported a neutron flux of 4,000 neutrons per second, as well as detection of tritium. The classical branching ratio for previously known fusion reactions that produce tritium would predict, with 1 watt of power, the production of 1012 neutrons per second, levels that would have been fatal to the researchers. In 2009, Mosier-Boss et al. reported what they called the first scientific report of highly energetic neutrons, using CR-39 plastic radiation detectors, but the claims cannot be validated without a quantitative analysis of neutrons. Several medium and heavy elements like calcium, titanium, chromium, manganese, iron, cobalt, copper and zinc have been reported as detected by several researchers, like Tadahiko Mizuno or George Miley. The report presented to the United States Department of Energy (DOE) in 2004 indicated that deuterium-loaded foils could be used to detect fusion reaction products and, although the reviewers found the evidence presented to them as inconclusive, they indicated that those experiments did not use state-of-the-art techniques.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.